Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00001091 · ClinicalTrials.gov registry record · Phase 1
Safety and Effectiveness of Four Anti-HIV Drug Combinations in HIV-Infected Children and Teens
A Phase 1 study of HIV Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 200
- Enrollment target
- 20
- Study locations
NCT00001091: Completed Phase 1 study of HIV Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT00001091 is a Phase 1 study of HIV Infections that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 200 participants, below the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (55% lower). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00001091, a Phase 1 study of HIV Infections, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 200 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to see if it is safe and effective to give HIV-infected children and teens 1 of 4 anti-HIV drug combinations. Decreasing HIV levels in infected patients can slow down disease progression. Further study is needed to find out which drug combinations are most effective in doing this.
Conditions Studied
Interventions
- DRUG Lamivudine
- DRUG Ritonavir
- DRUG Stavudine
- DRUG Nelfinavir mesylate
- DRUG Nevirapine
Study Locations (20)
California
- UCSD Med Ctr / Pediatrics / Clinical Sciences - La Jolla
- Long Beach Memorial (Pediatric) - Long Beach
- Children's Hosp of Los Angeles/UCLA Med Ctr - Los Angeles
- Los Angeles County - USC Med Ctr - Los Angeles
- UCLA Med Ctr / Pediatric - Los Angeles
- Harbor - UCLA Med Ctr / UCLA School of Medicine - Los Angeles
- Children's Hosp of Oakland - Oakland
- UCSF / Moffitt Hosp - Pediatric - San Francisco
Florida
- North Broward Hosp District - Fort Lauderdale
- Univ of Florida Gainesville - Gainesville
- Univ of Florida Health Science Ctr / Pediatrics - Jacksonville
- Palm Beach County Health Dept - Riviera Beach
District of Columbia
- Children's Hosp of Washington DC - Washington D.C.
- Washington Hosp Ctr - Washington D.C.
- Howard Univ Hosp - Washington D.C.
Connecticut
- Connecticut Children's Med Ctr - Pediatric - Hartford
- Yale Univ Med School - New Haven
Georgia
- Emory Univ Hosp / Pediatrics - Atlanta
- Med College of Georgia - Augusta
Alabama
- Univ of Alabama at Birmingham - Pediatric - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Est. Completion | 2000-10 |
| Phase | Phase 1 |
What the finished NCT00001091 record still lists
NCT00001091 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (55% lower).
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 5 interventions - of which Lamivudine is the first listed.
NCT00001091 names 20 study sites across 6 states, led by California, Florida, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT00001091 about?
NCT00001091 is a clinical study titled "Safety and Effectiveness of Four Anti-HIV Drug Combinations in HIV-Infected Children and Teens". The purpose of this study is to see if it is safe and effective to give HIV-infected children and teens 1 of 4 anti-HIV drug combinations. Decreasing HIV levels in infected patients can slow down disease progression. Further study is needed to find out which drug combinations are most effective in ...
What is the current status of trial NCT00001091?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 200 participants. Estimated completion is 2000-10.
What conditions does trial NCT00001091 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT00001091?
The interventions under investigation include: Lamivudine (DRUG), Ritonavir (DRUG), Stavudine (DRUG), Nelfinavir mesylate (DRUG), Nevirapine (DRUG).
Who is sponsoring clinical trial NCT00001091?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00001091 being conducted?
This trial has 20 study locations across Alabama, California, Connecticut, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00001091's enrollment target sits among peer trials
200 171st of 542 higher than 362 of 542 other HIV Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
CAR-T Cells for HIV Infection
RECRUITING · Phase 1
-
A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV
RECRUITING · Phase 1
-
Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Adult Participants Who Previously Participated in HVTN 706
RECRUITING · Phase 1
-
Pharmacokinetics, Safety, Tolerability of Dolutegravir/Rilpivirine in Pediatrics
RECRUITING · Phase 1
-
A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants
RECRUITING · Phase 1
-
First Time in Human Study of Long Acting VH4524184 Formulations
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes